doi: 10.1038/eye.2016.154.
Epub 2016 Aug 12.
Licence to save: a UK survey of anti-VEGF use for the eye in 2015
Affiliations
- PMID: 27518544
- PMCID: PMC5108014
- DOI: 10.1038/eye.2016.154
Item in Clipboard
Licence to save: a UK survey of anti-VEGF use for the eye in 2015
Eye (Lond).
2016 Nov.
No abstract available
Figures
The proportions of the different anti-VEGF injections performed in the UK for the month of January 2015.
Comment in
-
Comment on 'Licence to save: a UK survey of anti-VEGF use for the eye in 2015'.Eye (Lond). 2018 Feb;32(2):468. doi: 10.1038/eye.2017.177. Epub 2017 Aug 25. Eye (Lond). 2018. PMID: 28840854 Free PMC article. No abstract available.
Similar articles
-
The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective.PLoS One. 2018 May 17;13(5):e0197670. doi: 10.1371/journal.pone.0197670. eCollection 2018. PLoS One. 2018. PMID: 29772018 Free PMC article.
-
A longitudinal study to assess the frequency and cost of antivascular endothelial therapy, and inequalities in access, in England between 2005 and 2015.BMJ Open. 2017 Oct 22;7(10):e018289. doi: 10.1136/bmjopen-2017-018289. BMJ Open. 2017. PMID: 29061629 Free PMC article.
-
Healthcare resource use and costs of diabetic macular oedema for patients with antivascular endothelial growth factor versus a dexamethasone intravitreal implant in Korea: a population-based study.BMJ Open. 2019 Sep 20;9(9):e030930. doi: 10.1136/bmjopen-2019-030930. BMJ Open. 2019. PMID: 31542758 Free PMC article.
-
Open Payments Database: Anti-Vascular Endothelial Growth Factor Agent Payments to Ophthalmologists.Am J Ophthalmol. 2017 Jan;173:91-97. doi: 10.1016/j.ajo.2016.09.026. Epub 2016 Sep 30. Am J Ophthalmol. 2017. PMID: 27697472
-
Cost and Selection of Ophthalmic Anti-Vascular Endothelial Growth Factor Agents.R I Med J (2013). 2016 May 2;99(5):15-7. R I Med J (2013). 2016. PMID: 27128510 Review.
Cited by
-
Off-label use of bevacizumab for wet age-related macular degeneration in Europe.Graefes Arch Clin Exp Ophthalmol. 2020 Mar;258(3):503-511. doi: 10.1007/s00417-019-04569-8. Epub 2019 Dec 30. Graefes Arch Clin Exp Ophthalmol. 2020. PMID: 31889214 Review.
-
Protein and polypeptide mediated delivery to the eye.Adv Drug Deliv Rev. 2022 Sep;188:114441. doi: 10.1016/j.addr.2022.114441. Epub 2022 Jul 9. Adv Drug Deliv Rev. 2022. PMID: 35817213 Free PMC article. Review.
-
Harnessing the Neuroprotective Behaviors of Müller Glia for Retinal Repair.Front Biosci (Landmark Ed). 2022 May 30;27(6):169. doi: 10.31083/j.fbl2706169. Front Biosci (Landmark Ed). 2022. PMID: 35748245 Free PMC article. Review.
-
Exploring factors predicting changes in patients' expectations and psychosocial issues during the course of treatment with intravitreal injections for wet age-related macular degeneration.Eye (Lond). 2018 Apr;32(4):673-678. doi: 10.1038/eye.2017.271. Epub 2017 Dec 8. Eye (Lond). 2018. PMID: 29219960 Free PMC article.
-
A systematic review to assess the 'treat-and-extend' dosing regimen for neovascular age-related macular degeneration using ranibizumab.Eye (Lond). 2017 Sep;31(9):1337-1344. doi: 10.1038/eye.2017.67. Epub 2017 May 5. Eye (Lond). 2017. PMID: 28475181 Free PMC article.
References
-
- Lock D. Avastin and Lucentis: a guide through the legal maze. BMJ 2015; 350: h1377. - PubMed
-
- Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013; 382: 1258–1267. - PubMed
-
- Virgili G, Parravano M, Menchini F, Evans JR. Anti-vascular endothelial growth factor for diabetic macular oedema. Cochrane Database Syst Rev 2014; 10: CD007419. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
